Suppression of rat deoxycorticosterone-salt hypertension by kallikrein-kinin system.

Author:

Majima M1,Katori M1,Hanazuka M1,Mizogami S1,Nakano T1,Nakao Y1,Mikami R1,Uryu H1,Okamura R1,Mohsin S S1

Affiliation:

1. Department of Pharmacology, Kitasato University School of Medicine, Kanagawa, Japan.

Abstract

Brown Norway kininogen-deficient rats had very low levels of plasma kininogens and lower levels of plasma prekallikrein, compared with those of normal rats of the same strain. Systolic blood pressure, determined by the tail-cuff method, of 5-week-old kininogen-deficient rats (106 +/- 0.4 mm Hg, n = 7) and the rate of systolic blood pressure increase with age were not different from those in normal rats. Weekly injections of deoxycorticosterone acetate (5 mg/kg s.c.) with 1% sodium chloride solution in drinking water after uninephrectomy at 7 weeks of age caused a gradual increase in the blood pressure of normal rats, reaching a plateau at 18 weeks of age, whereas that of deficient rats rose rapidly to 158 +/- 6 mm Hg 2 weeks after the start of treatment and continued to increase slightly, becoming significantly higher than normal rats at 8, 9, 10, 11, and 12 weeks of age (p less than 0.05 or 0.01). The levels of urinary prokallikrein and active kallikrein were slightly higher in deficient rats before deoxycorticosterone acetate-salt treatment but were not significantly increased after this treatment, whereas these levels in normal rats were increased 3.6- and 4.7-fold by this treatment. Urinary free kinin, collected from the ureter in untreated deficient rats, was below the detection limit. The plasma level of low molecular weight kininogen, the substrate of glandular kallikrein, was decreased in normal rats during the treatment. Continuous subcutaneous injection of aprotinin by an osmotic pump to normal rats induced significant increase in blood pressure. These results indicate that glandular kallikrein may play a suppressive role in deoxycorticosterone acetate-salt hypertension.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Internal Medicine

Reference42 articles.

1. THE URINARY EXCRETION OF A DEPRESSOR SUBSTANCE (KALLIKREIN OF FREY AND KRAUT) IN ARTERIAL HYPERTENSION*

2. ALTERED URINARY KALLIKREIN EXCRETION IN HUMAN HYPERTENSION

3. Urinary kallikrein excretion in hypertension;Margolius HS;Ore Res,1972

4. Urinary kallikrein excretion in normal man: Relationships to sodium intake and sodium-retaining steroids;Margolius HS;Ore Res,1974

5. Studies on rat renal cortical cell kallikrein I. Separation and measurement

Cited by 77 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Activity Methods for Cardiovascular System Diseases;Methods for Preclinical Evaluation of Bioactive Natural Products;2023-06-25

2. Role of Kinins in Hypertension and Heart Failure;Pharmaceuticals;2020-10-28

3. Invasomes of isradipine for enhanced transdermal delivery against hypertension: formulation, characterization, and in vivo pharmacodynamic study;Artificial Cells, Nanomedicine, and Biotechnology;2016-02-01

4. Methods to Induce Experimental Hypertension;Drug Discovery and Evaluation: Pharmacological Assays;2016

5. Methods to Induce Experimental Hypertension;Drug Discovery and Evaluation: Pharmacological Assays;2014

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3